التفاصيل البيبلوغرافية
| العنوان: |
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial |
| المؤلفون: |
Morgan, Robert D., McNeish, Iain A., Cook, Adrian D., James, Elizabeth C., Lord, Rosemary, Dark, Graham, Glasspool, Rosalind M., Krell, Jonathan, Parkinson, Christine, Poole, Christopher J., Hall, Marcia, Gallardo-Rincón, Dolores, Lockley, Michelle, Essapen, Sharadah, Summers, Jeff, Anand, Anjana, Zachariah, Abel, Williams, Sarah, Jones, Rachel, Scatchard, Kate, Walther, Axel, Kim, Jae-Weon, Sundar, Sudha, Jayson, Gordon C., Ledermann, Jonathan A., Clamp, Andrew R. |
| بيانات النشر: |
Elsevier |
| سنة النشر: |
2021 |
| المجموعة: |
RD&E Research Repository (Royal Devon and Exeter NHS Foundation Trust) |
| مصطلحات موضوعية: |
Humans, Aged, Female, Middle Aged, Australia, CA-125 Antigen, Carboplatin/*administration & dosage/adverse effects, Disease-Free Survival, Fallopian Tube Neoplasms/*drug therapy/genetics/pathology, Fallopian Tubes/pathology, Ireland, Membrane Proteins, Neoadjuvant Therapy/adverse effects, New Zealand, Ovarian Neoplasms/*drug therapy/genetics/pathology, Paclitaxel/*administration & dosage/adverse effects, Peritoneal Neoplasms/*drug therapy/genetics/pathology, Response Evaluation Criteria in Solid Tumors |
| الوصف: |
BACKGROUND: Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been validated in randomised, phase 3 trials, evaluation of response to neoadjuvant chemotherapy using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST), and cancer antigen 125 (CA125) has not been reported. We describe RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responses in patients receiving platinum-based neoadjuvant chemotherapy followed by DPS in the ICON8 trial. METHODS: ICON8 was an international, multicentre, randomised, phase 3 trial done across 117 hospitals in the UK, Australia, New Zealand, Mexico, South Korea, and Ireland. The trial included women aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, life expectancy of more than 12 weeks, and newly diagnosed International Federation of Gynecology and Obstetrics (FIGO; 1988) stage IC-IIA high-grade serous, clear cell, or any poorly differentiated or grade 3 histological subtype, or any FIGO (1988) stage IIB-IV epithelial cancer of the ovary, fallopian tube, or primary peritoneum. Patients were randomly assigned (1:1:1) to receive intravenous carboplatin (area under the curve [AUC]5 or AUC6) and intravenous paclitaxel (175 mg/m(2) by body surface area) on day 1 of every 21-day cycle (control group; group 1); intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 2); or intravenous dose-fractionated carboplatin (AUC2) and intravenous dose-fractionated paclitaxel (80 mg/m(2) by body surface area) on days 1, 8, and 15 of every 21-day cycle (group 3). The maximum number of cycles of chemotherapy permitted was six. Randomisation was done with a minimisation method, and patients were stratified according to GCIG group, disease stage, and ... |
| نوع الوثيقة: |
other/unknown material |
| اللغة: |
English |
| العلاقة: |
https://doi.org/10.1016/S1470-2045Test(20)30591-X; Morgan, R. D. et al. (2021) ‘Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.’, The Lancet. Oncology, 22(2), pp. 277–288. doi:10.1016/S1470-2045(20)30591-X.; https://rde.dspace-express.com/handle/11287/622079Test; The Lancet. Oncology |
| DOI: |
10.1016/S1470-2045(20)30591-X |
| الإتاحة: |
https://doi.org/10.1016/S1470-2045Test(20)30591-X
https://rde.dspace-express.com/handle/11287/622079Test |
| حقوق: |
Copyright © 2021 Elsevier Ltd. All rights reserved. |
| رقم الانضمام: |
edsbas.9FE5FAA8 |
| قاعدة البيانات: |
BASE |
